Persistent Fetal Vasculature: Mechanisms of Development, Current Treatment Approaches, and Advancements in Therapy
-
By
-
Robert H. Henderson
-
October 6, 2026
By
Robert H. Henderson
October 6, 2026
by Robert H. Henderson
October 6, 2026
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026